Long-term survival rates after a diagnosis of breast cancer are steadily rising. This is good
news, but clinicians must also recognize that this brings new challenges to the medical …

Background Several guidelines have been reported for bone-directed treatment in women
with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor …

PURPOSE The aim of this work is to provide evidence-based guidance on the management
of osteoporosis in survivors of adult cancer. METHODS ASCO convened a multidisciplinary …

Purpose To develop evidence-based guidelines, based on a systematic review, for
endocrine therapy for postmenopausal women with hormone receptor–positive breast …

Aromatase inhibitors (AIs) are a key component in the chemoprevention and treatment of
hormone receptor-positive (HR+) breast cancer. While the addition of AI therapy has …

Drug-induced osteoporosis is common and has a significant impact on the prognosis of
patients suffering from chronic debilitating diseases. Glucocorticoids are the drugs causing …

Breast cancer is the most common malignancy in women in the United States and is second
only to lung cancer as a cause of cancer death. The overall management of breast cancer …

Ziele Das Ziel dieser offiziellen Leitlinie, die von der Deutschen Gesellschaft für
Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) …

Preservation of bone health remains a long-term clinical challenge in patients with breast
and prostate cancer. Osteoporosis, defined by a loss of bone mass and microarchitecture …

Background Bone mineral density (BMD)-based guidelines for bone-directed therapy in
women with early breast cancer (EBC) appear inadequate for averting fractures, particularly …